Format

Send to

Choose Destination
Br J Cancer. 2015 Jul 14;113(2):199-203. doi: 10.1038/bjc.2015.215. Epub 2015 Jun 30.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.

Author information

1
Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
2
AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
3
AstraZeneca, Gatehouse Park, Waltham, MA 02451, USA.
4
Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.
5
Instituto Brasileiro de Cancerologia Torácica, Rua Dr. Martinico Prado, 26/101, Higienópolis, Sao Paulo 01224-010, Brazil.
6
Department of Pneumology, Hôpital Gabriel Montpied, 58 Rue Montalembert, 63000 Clermont-Ferrand, France.
7
Department of Pneumology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
8
Department of Medicine, PUCRS School of Medicine, Padre Chagas 66, 203, Porto Alegre RS 90 570 080, Brazil.
9
CACON, Hospital de Caridade de Ijuí, Avenida David José Martins, 152-Centro, Ijuí RS 98700-000, Brazil.
10
Department of Oncology, University Medical School Perugia, Piazza Università 1, 06123 Perugia, Italy.

Abstract

BACKGROUND:

Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825).

METHODS:

Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations.

RESULTS:

In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations.

CONCLUSION:

Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.

PMID:
26125448
PMCID:
PMC4506393
DOI:
10.1038/bjc.2015.215
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center